ARCHIVES

FDA To Expand Disclosure For Advisory Committee Members

This article is from The Cancer Letter archive.

Vol. 36 No. 15 | April 23, 2010

Download PDF Visit The Full Archive

Related Articles

NCI Forms New Committees to Oversee Cancer Clinical Trials.

February 17, 2006

Nader Group Backs FDA In controversy Over Drug Testing

February 11, 1977

Ethics Commission Acknowledges Weak Case For Mandatory Patient Compensation

April 23, 1982

VP Joe Biden Will Not Host Komen’s Global Race for the Cure in D.C.

May 11, 2012

GAO Criticizes Distribution Of Comprehensive Cancer Centers, Cite Needs for “Focal Point” Clarification

March 26, 1976

Interim Analysis of Phase III Data Preferable For Accelerated Approval, FDA’s Pazdur Says

September 6, 2002